These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3812538)

  • 1. Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis.
    McCarthy JT; Kurtz SB; Mussman GV
    Am J Med; 1987 Feb; 82(2):367-70. PubMed ID: 3812538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferoxamine for the treatment of hemosiderosis during CAPD.
    Gomez RA; Campbell F; Savory J; Chevalier RL
    Int J Pediatr Nephrol; 1987; 8(1):21-4. PubMed ID: 3583552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic aluminum poisoning in continuous ambulatory peritoneal dialysis: treatment with deferoxamine].
    Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK
    Dtsch Med Wochenschr; 1989 Feb; 114(7):253-7. PubMed ID: 2917487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
    Krüger N; Kijewski H; König R; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1682-5. PubMed ID: 6489181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes of metal concentrations in blood and peritoneal dialysate during long-term desferrioxamine B therapy.
    Romero RA; Salgado O; Elejalde LE; Rodríguez-Iturbe B; Tahán JE
    Transplant Proc; 1996 Dec; 28(6):3385-7. PubMed ID: 8962321
    [No Abstract]   [Full Text] [Related]  

  • 6. Detoxification in hemosiderosis.
    Simon P
    Blood Purif; 1985; 3(1-3):75-88. PubMed ID: 3913449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy.
    Navarro JA; Granadillo VA; Rodríguez-Iturbe B; García R; Salgado O; Romero RA
    Clin Nephrol; 1991 May; 35(5):213-7. PubMed ID: 1855329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferoxamine and aluminum removal.
    Swartz RD
    Am J Kidney Dis; 1985 Nov; 6(5):358-64. PubMed ID: 3904429
    [No Abstract]   [Full Text] [Related]  

  • 9. Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: association with deferoxamine.
    Nakamura M; Weil WB; Kaufman DB
    Pediatr Nephrol; 1989 Jan; 3(1):80-2. PubMed ID: 2702092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis.
    Andreoli SP; Dunn D; DeMyer W; Sherrard DJ; Bergstein JM
    J Pediatr; 1985 Nov; 107(5):760-3. PubMed ID: 3932629
    [No Abstract]   [Full Text] [Related]  

  • 11. Aluminum removal by peritoneal dialysis: intravenous vs. intraperitoneal deferoxamine.
    Hercz G; Salusky IB; Norris KC; Fine RN; Coburn JW
    Kidney Int; 1986 Dec; 30(6):944-8. PubMed ID: 3820944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aluminum and deferoxamine kinetics in CAPD.
    Mactier RA
    Adv Perit Dial; 1991; 7():26-9. PubMed ID: 1680440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron removal during continuous ambulatory peritoneal dialysis using deferoxamine.
    Falk RJ; Mattern WD; Lamanna RW; Gitelman HJ; Parker NC; Cross RE; Rastall JR
    Kidney Int; 1983 Jul; 24(1):110-2. PubMed ID: 6620847
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of intravenous and intraperitoneal desferrioxamine in aluminium osteomalacia.
    O'Brien AA; McParland C; Keogh JA
    Nephrol Dial Transplant; 1987; 2(2):117-9. PubMed ID: 3112649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of iron and aluminum related osteomalacia in a long-term hemodialysis patient].
    Yamagata K; Kobayashi M; Koyama A; Narita M; Amagai H; Ohno A; Yoshikawa S
    Nihon Jinzo Gakkai Shi; 1991 Apr; 33(4):437-42. PubMed ID: 1875564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma amino acid levels and amino acid losses during continuous ambulatory peritoneal dialysis.
    Kopple JD; Blumenkrantz MJ; Jones MR; Moran JK; Coburn JW
    Am J Clin Nutr; 1982 Sep; 36(3):395-402. PubMed ID: 7113946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation.
    Molitoris BA; Alfrey PS; Miller NL; Hasbargen JA; Kaehney WD; Alfrey AC; Smith BJ
    Kidney Int; 1987 Apr; 31(4):986-91. PubMed ID: 3586503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histochemical demonstration of iron but not aluminum in a case of dialysis-associated osteomalacia.
    Phelps KR; Vigorita VJ; Bansal M; Einhorn TA
    Am J Med; 1988 Apr; 84(4):775-80. PubMed ID: 3041812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of desferrioxamine and of its iron and aluminum chelates in patients on peritoneal dialysis.
    Allain P; Chaleil D; Mauras Y; Varin MC; Ang KS; Cam G; Simon P
    Clin Chim Acta; 1988 Apr; 173(3):313-6. PubMed ID: 3383431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.